In the Boardroom
Refine search
Biotechnology
UK-based 4basebio, a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, says it has promoted Christine Wolosin to chief commercial officer. 3 March 2026
Pharmaceutical
Scotland-based contract development and manufacturing organization (CDMO) Symbiosis Pharmaceutical Services, a specialist in the GMP sterile fill-finish manufacturing of injectable drug products, has announced the appointment of Joanne Anderson as its chief commercial officer (CCO). 3 March 2026
Biotechnology
Danish vaccine maker Bavarian Nordic announced today, that the board of directors has entered into an agreement with CEO, Paul Chaplin, who wishes to step down for personal reasons. 3 March 2026
Biotechnology
California-based immunotherapy company 3T Biosciences has appointed Rebeca Villarreal-Barragan as head of clinical operations. In this role, Ms Villarreal-Barragan will lead all aspects of clinical operations as the company advances its pipeline of T-cell receptor (TCR)-based therapeutics for solid tumors. 3 March 2026
Generics
Hikma Pharmaceuticals today reported its audited results for the year ended December 31, 2025. The company’s shares were down almost 15% at 1,406 pence by early afternoon. 26 February 2026
Biotechnology
Douglas Ingram has told Sarepta Therapeutics of his decision to retire as chief executive of the US genetic medicines company by the end of 2026 or upon the appointment of his replacement. 26 February 2026
Pharmaceutical
Ireland headquartered Alkermes (Nasdaq: ALKS) has announced that Richard Pops will retire from his role as chief executive (CEO), effective July 31, 2026. 26 February 2026
Pharmaceutical
UK biotech N4 Pharma has appointed David Solomon as chief executive and unveiled plans to rename itself Thalia Therapeutics, marking a decisive shift into proprietary RNA medicines focused initially on cardiovascular disease. 24 February 2026
Pharmaceutical
Danish allergy immunotherapy specialist ALK Abello has announced that Henriette Mersebach will step down imminently as executive vice president, research and development, and as a member of the board. 20 February 2026
Pharmaceutical
Japanese drugmaker Daiichi Sankyo has appointed Dr John Tsai as its new global head of R&D, to succeed Dr Ken Takeshita, who is stepping down from his post effective April 1, 2026. 20 February 2026
Biotechnology
Spain-based Biofabri, the human vaccines subsidiary of the biopharmaceutical group Zendal, has added Rolando Pajón Feyt, an international expert in immunotherapy and vaccine development, to its management team to strengthen the final phase of clinical development of its tuberculosis vaccine candidate, MTBVAC. 17 February 2026
Biotechnology
French clinical-stage biotech Sensorion, which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announced that Nawal Ouzren, Sensorion’s chief executive (CEO) and a director of the company, is stepping down from both posts due to a personal matter incompatible with serving as CEO. 17 February 2026
Biotechnology
UK based clinical-stage biotech Artios Pharma today announced the appointment of three senior leaders to strengthen its late-stage development capabilities and preparation for commercial readiness. 16 February 2026
Biotechnology
Juvenescence, an Abu Dhabi, UAE-based clinical-stage AI-enabled biotech company developing novel medicines to extend healthy lifespan, today announced the appointment of Eileen Jennings-Brown as chief technology officer. 16 February 2026
Biotechnology
UK biotech Nucleome Therapeutics has appointed Dr Michelle Morrow as chief scientific officer, as it pushes ahead with a pipeline aimed at the molecular roots of inflammatory disease. 16 February 2026
Pharmaceutical
US dermatology specialist Verrica Pharmaceuticals has announced the appointment of Chris Chapman as its chief commercial officer (CCO). 13 February 2026
Biotechnology
US biotech major Biogen has elected Maria Freire as chair of the board of directors. 12 February 2026
Pharmaceutical
French pharma major Sanofi's board of directors has decided not to renew the director mandate of Paul Hudson. As a result, Paul Hudson’s last day as chief executive (CEO) will be on February 17, 2026 at the end of business. 12 February 2026
Biotechnology
Australia’s CSL Limited has announced that Paul McKenzie will immediately retire as the group’s chief executive and managing director after three years. 11 February 2026
Pharmaceutical
German CDMO Rentschler Biopharma has appointed Veit Bergendahl as chief operating officer and a member of its executive board, effective from April. 11 February 2026
Pharmaceutical
Dutch contract research, development and manufacturing organization Symeres has appointed Henning Steinhagen as chief executive, handing leadership to a drug discovery executive with deep roots in the outsourced pharma services sector. 6 May 2026
Biotechnology
UK based clinical-stage biotech Artios Pharma yesterday announced the appointment of three senior executives to the leadership team as the company accelerates its potential first-in-class oncology pipeline. 5 May 2026
Pharmaceutical
US drug delivery specialist Halozyme Therapeutics has appointed Darren Snellgrove as chief financial officer, effective June 8, 2026. 1 May 2026
Biotechnology
US biotech Cue Biopharma has set out a three-part reset, appointing Shao-Lee Lin as chief executive, licensing a clinical-stage anti-IgE antibody and raising $30 million to fund its next pha 1 May 2026
Biotechnology
US late-stage biotech Immunic today announced that it has appointed Dr Michael Panzara as chief medical officer (CMO), effective April 24, 2026. 28 April 2026
Biotechnology
Denmark-based clinical-stage company Evaxion), which is developing novel vaccines with its pioneering AI-Immunology platform, announced that Birgitte Rønø, its chief scientific Officer (CSO), will take on the dual responsibilities of CSO and chief operating officer (COO). 27 April 2026
Pharmaceutical
German biotech Evotec has said chief financial officer Paul Hitchin will step down on April 30 for personal reasons, after just over a year in the role. 24 April 2026
Biotechnology
US biotech major Amgen has announced the retirement of David Reese, executive vice president and chief technology officer, effective June 30. 23 April 2026
Pharmaceutical
US biotech Madrigal Pharmaceuticals has appointed Ricardo Rocha as executive vice president and global head of medical affairs, adding senior clinical leadership as it scales commercialization around its recently launched liver disease drug. 23 April 2026
Pharmaceutical
Swiss specialty pharma company Santhera Pharmaceuticals has appointed Orlando Oliveira as chief executive (CEO), effective July 15, 2026. 23 April 2026
Biotechnology
German contract development and manufacturing company ProBioGen announced the appointment of Dr Simon Johannes Bulling as chief operating officer (COO), effective April 15, 2026. 22 April 2026
Biotechnology
US clinical-stage biotech Neurogene today announced the appointment of Christy Shafer as chief commercial officer and the appointment of Christine Mikail to its board of directors. 20 April 2026
Pharmaceutical
Achieve Life Sciences, a late-stage specialty pharma company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, has appointed Andrew Goldberg as its new chief executive and member of the board. 17 April 2026
Pharmaceutical
UK-based specialty pharma company CNX Therapeutics today announced the appointment of David Flint as chief corporate development officer (CCDO), effective April 7, 2026. 16 April 2026
Biotechnology
Enodia Therapeutics, a privately-held French biotech developing small molecule therapies targeting a unique form of protein degradation at the point of synthesis, has appointed Yvonne McGrath as chief scientific officer (CSO). 15 April 2026
Biotechnology
French immunotherapy company OSE Immunotherapeutics provided a senior management update. 15 April 2026
Biotechnology
German drug discovery company Evotec today announced the appointment of Dr Ingrid Müller as chief operating officer (COO). 15 April 2026
Biotechnology
Dutch biotech Laigo Bio, which is pioneering novel and highly differentiated therapies using its proprietary SureTACs precision membrane protein degradation platform, has appointed Dr Richard Sainson as its new chief scientific officer (CSO). 14 April 2026
Pharmaceutical
Lotte Bjerre Knudsen, chief scientific advisor to the chief scientific officer, vice president of innovation and data experimentation advancement (IDEA) at Danish pharma major Novo Nordisk, is to leave the company after 36 years. 13 April 2026
Biotechnology
Canada-based biotech Zymeworks today announced the full-time appointments of Dr Adam Schayowitz and Scott Platshon as of April 9, 2026, from their previously interim roles. 9 April 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze